Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here .

Good morning. Who’s running a turkey trot in a few days? I need to start stretching now.

FDA reviewers didn’t get to vote on first priority voucher drug

Typically, the FDA’s drug approval decisions are made by the individual reviewers most familiar with a treatment’s application and the science behind it. But when the agency held its vote for the first product from a company that received a priority voucher , the review team did not get a say. Instead, the voting panelists were leaders from the top of the agency, according to three agency sources who talked with STAT’s Lizzy Lawrence.

“This is overtly political,” said bioethics and law professor Holly Fernandez Lynch

See Full Page